

DR GEOFFREY D BARNES (Orcid ID : 0000-0002-6532-8440)

DR MARY CUSHMAN (Orcid ID : 0000-0002-7871-6143)

Article type : Letter - to the Editor

Response

Geoffrey D. Barnes, MD, MSc

University of Michigan - Cardiovascular Center

Mary Cushman, MD, MSc

Correspondence:

Mary Cushman, MD, MSc, FAHA

University of Vermont

Medicine & Pathology

Department of Medicine

360 South Park Drive

Colchester, VT

05446

Phone: 802-656-8968

mary.cushman@uvm.edu

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/RTH2.12452](https://doi.org/10.1002/RTH2.12452)

This article is protected by copyright. All rights reserved

We thank Dr. Højen and colleagues for their interest in our position paper on venous thromboembolism (VTE) research priorities. We strongly agree that patient and caregiver engagement in the research process strengthens the investigative process. We include a few examples here following the framework of our article and agree that many more (and likely more impactful) ideas will be generated when patients, family, and other stakeholders are engaged in the investigative process.

For fundamental research (T0) patient and stakeholder engagement may help to identify previously unrecognized connections that hypothesize potential molecular mechanisms connecting pathology with clinical presentation. For human level research (T1), patient and stakeholder engagement may influence the selection of new anticoagulant targets based on the impact of drug delivery methods. For patient level research (T2), identifying patient-centered outcomes for measuring efficacy of treatments may change the design of clinical trials and interpretation of results. For practice level research (T3), the patient, family, and stakeholder voices are critical for understanding and overcoming barriers to implementing evidence into practice. And for community and population level research (T4), patients and stakeholders must be equal or leading partners in addressing public awareness and policy prioritization of VTE and VTE preventative measures.

We thank Dr. Højen and colleagues for raising this important topic. We fully support the engagement of patients, family, and other stakeholders in all levels and steps of the VTE research process.